Introduction
Acute lymphoblastic leukemia (ALL) is characterized by an excessive accumulation of lymphoblasts and their progenitor cells. 1 ALL is the most frequent childhood cancer and accounts for approximately 25% of adult acute leukemias. 1 In approximately 80%
of cases, ALL arises from B-cell lineage progenitor cells, whereas 20% are derived from T-cell lineage precursors. 2 The diagnosis of ALL is based on immunophenotyping, which allows lineage assignment as well as the identification of prognostically important disease subtypes. 3;4 Furthermore, chromosomal aberrations have been shown to confer prognostically highly relevant information and are used to stratify patients according to different treatment regimens. 1 Today, virtually all patients with ALL can be classified according to specific genetic abnormalities. 5 In addition, molecular analyses have shown that ALL subtypes harbor specific gene expression signatures, e.g. depending on the cell lineage or cytogenetic abnormalities, 6 carry specific DNA copy number alterations, 7 or molecular alterations such as mutations in single genes, e.g. IKZF1.
5;8
T-ALL, in particular, has been demonstrated to represent a heterogeneous disease with genetic subgroups that correspond to specific T-cell development stages, genomic alterations leading to deregulated expression of genes, e.g. BAALC, ERG, TAL1 or LMO2, as well as harboring deletions or mutations of genes such as PTEN, NOTCH1 or FBXW7.
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The runt-related transcription factor 1, RUNX1, located on chromosome 21q22, is essential in the development of all hematopoietic cell lineages, including lymphoid cells, 9 and contains an 128-amino acid Runt domain (RUNT) and an 80-amino acid transactivation domain (TAD) . 10 Through the RUNT domain, RUNX1 is able to bind to a common DNA motif of its targets and this domain also mediates the 4 heterodimerization with CBFβ, which increases DNA binding activity to RUNX proteins. 10 Further, RUNX1 both increases and inhibits transcriptional activity of target genes, depending on the cellular background and pathway. 10 RUNX1 has been described to be mutated in AML (32%), 11 MDS (23%), 12 and CMML (37%), 13 and is associated with a shorter overall and event-free survival in AML, respectively. 11;14 Moreover, the gene is involved in a multitude of chromosomal translocations, e.g. the translocation t(12;21)(p13;q22) (ETV6-RUNX1) in B-cell ALL cases, in which the TAD domain but not the RUNT domain of RUNX1 is retained in the fusion gene. In contrast, in the majority of other translocations involving RUNX1, e.g. t(8;21)(q22;q22) (RUNX1-RUNX1T1), the RUNT domain is retained in the fusion genes. 15 Truncated RUNX1 proteins act as dominant negative inhibitors of the wildtype protein by binding of DNA through the RUNT domain, therefore the wild-type protein lost its ability to regulate target genes. 16 In a recent study investigating 39 patients with chronic myeloid leukemia in blast crisis (BC-CML) with either myeloid or lymphoid features, three out of ten patients with a lymphoid BC-CML harbored a RUNX1 mutation indicating a so far not discussed potential role of RUNX1 alterations in lymphatic malignancies. 17 Here, we analyzed the RUNX1 mutation status in a cohort of 128 adult patients harboring T-ALL, B-ALL, or natural killer (NK) cell leukemia to further study the impact of RUNX1 alterations in de novo acute lymphoblastic leukemias. Multiparameter flow cytometry (MFC) was performed by applying five-color stainings and isotype controls with monoclonal antibodies conjugated with the fluorochromes FITC, PE, ECD, PC-5, and PC-7. Samples were processed as described previously. 18 MFC analyses were performed using FC500 and Navios flow cytometers (Beckman Coulter, Miami, FL). List mode files were analyzed using CXP Software version 2.0 and Kaluza version 1.0 (Beckman Coulter). Diagnoses were assigned according to EGIL and WHO classifications. 1;3 For molecular analyses, a sensitive next-generation amplicon deep-sequencing assay (NGS) was applied, using the small volume Titanium amplicon chemistry (454 Life Sciences, Branford, CT). A sequencing library was prepared interrogating the complete coding region of RUNX1, split into 7 distinct PCR amplicons (transcript identifier: ENST00000344691). Data on primer sequences, molecular barcodes used and the PCR amplification protocol are available online (Supplementary Table S1 , S2, and S3). NGS data were analyzed using the GS Variant Analyzer Software 2.5.3
Design and Methods

Peripheral
(454 Life Sciences) and Sequence Pilot version 3.4.2 (JSI Medical Systems, Kippenheim, Germany). All variants reported were independently validated using
Sanger sequencing or a separate setup of NGS PCR, emPCR and sequencing run.
Statistical analyses were performed using SPSS version 14.0.1 (SPSS Inc., Chicago, IL). Reported p-values are two-sided and not corrected for multiple testing.
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Results and Discussion
RUNX1 was successfully analyzed in all cases, i.e. in total 896 PCR amplicons were generated for the subsequent characterization by next-generation deep-sequencing.
In median, 776 reads per amplicon and patient (range 217-1654) were obtained, thus yielding a sufficient coverage for mutation detection with high sensitivity (<5%).
Overall, 17 mutations were detected in 15 patients. In the cohort of B-cell ALL, 2 of 52 cases were found to be RUNX1 mutated, both of them exclusively detected in the subgroup of patients harboring a BCR-ABL1 translocation (n=2/22 BCR-ABL mutated B-cell ALL). In T-ALLs, 15 distinct mutations were observed in 13/71 cases (18.3%).
Interestingly, 8 cases were harboring an early T-ALL (8/30, 26.6%) and only two cases a cortical T-ALL (2/30, 6.6%); subgroup data of three RUNX1 mutated cases are not available ( Figure 1a ).
In more detail, 17 different RUNX1 mutations were observed in 15 patients ( Figure   1b ): 8 missense alterations, 1 nonsense mutation, 7 frame shift alterations, and 1 inframe insertion. 2 of the 15 affected patients concomitantly harbored two distinct RUNX1 mutations. In both cases, these were located on two separate amplicons thus not allowing the discrimination between a mono-or biallelic state. As shown in Figure   1b , the RUNX1 mutations were generally distributed across several exons, but exclusively clustered in the RUNT (amino acid 50-177, 13/17 mutations) and TAD domain (amino acid 291-371; 4/17 mutations). The double-mutated cases were harboring a mutation affecting each of the two domains ( Figure 1b) .
As assessed by the percentage of single sequencing reads carrying the alteration, the median burden of RUNX1 mutations was 42% (range: 6% to 53%) per patient.
Information on blast count and clonality as detected by FISH or cytogenetics are given in the Supplemental Spreadsheet 1. Moreover, for one patient carrying the 7 Ser114Pro mutation (case number 2), a paired DNA sample from the remission and relapse state was available. At remission, the Ser114Pro mutation was undetectable, thus confirming the somatic nature as disease-specific alteration at diagnosis. In the relapse sample the mutation had emerged again with a clonality of 10%.
Here, we not only demonstrated for the first time the very high incidence of RUNX1 mutations in T-ALL, but also addressed the clinical impact of RUNX1 mutations detected with great detail. We observed that RUNX1 mutations in T-ALL were associated with a higher age (mean±SD 42±18 vs. 56±18 years; P=0.017), and lower white blood cell count (mean±SD 82±96 10 9 /L vs. 38±45 10 9 /L cell count; P=0.038),
but not with platelet count, hemoglobin level, gender or karyotype (Table 2 ).
Furthermore, a trend for a higher incidence of RUNX1 mutations in the subgroup of early T-ALL was detected (P=0.038).
Moreover, the most interesting observation from a clinical point of view was the negative impact of RUNX1 mutations on the overall survival in T-ALL. First, when taking the complete cohort into account, we observed a generally poor survival for RUNX1 mutated cases (alive at 2 years: 44.4% mutated vs. 66.6% wild-type patients;
P=0.011; Supplementary Figure S1 ). Secondly, we confirmed that the cortical immunophenotype had a positive effect on the overall survival of T-ALL patients (including the 63 cases with the known subtype; alive at 2 years: 82.1% vs. 42.8%;
P=0.002; Supplementary Figure S2) . 19 A multivariable analysis further demonstrated the cortical T-ALL subtype to be an independent prognostic parameter (P=0.016) and indicated for RUNX1 mutations a strong trend for an independent prognostic impact (P=0.062). Since in the cortical T-ALL patients only 6.6% (2/30) were carrying RUNX1 mutations and no mutation was observed in the 3 cases with the mature subtype, we next restricted the analysis of the prognostic impact of RUNX1 mutations to early T-ALL. In this subtype, 26.6% (8/30) of patients carried a mutation in RUNX1.
Again, mutated RUNX1 conferred a poor prognosis (alive at 2 years: 28.6% mutated vs. 46.0% wild-type patients; P=0.043; Figure 1c ).
Thus far, RUNX1 mutations have been described in myeloid malignancies such as AML and MDS. 11-13 In our T-ALL cohort, the location of mutations was observed to be similar in comparison to AML and MDS, as well as in families carrying RUNX1
germline mutations predisposing to platelet disorders and other myeloid malignancies. 20 Generally, with respect to its involvement in hematopoietic processes, RUNX1 has been shown to play a fundamental part in differentiation and that its role would not be limited to myeloid differentiation only. 21 As reported by Wong et al, RUNX1 has been demonstrated to be involved in lymphoid differentiation, which is particularly true for T-cell differentiation. mutations were exclusively detected in BCR-ABL1 positive cases, which are known to frequently co-express myeloid markers such as CD13 and CD33. 20 This may further point to a potential correlation of RUNX1 mutations that can be found in myeloid neoplasms but also in lymphatic leukemias demonstrating also some myeloid features.
Moreover, mutated RUNX1 has been proposed to represent a clinically useful biomarker to indicate disease progression from MDS to s-AML, 22 as well as a characteristic to monitor minimal residual disease (MRD) during AML treatment.
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While clonal rearrangements of T-cell receptor (TCR) genes also enable MRD assessment, these analyses are time-consuming and expensive. 24 As such, in 9 addition to the significant relevance of RUNX1 mutations with respect to survival, also monitoring of MRD in T-ALL can be accomplished by investigating for RUNX1 alterations in combination with next-generation deep-sequencing and generating thousands of reads for a patient-specific mutation.
In conclusion, we here demonstrated for the first time the fundamental importance of RUNX1 mutation assessment in hematological diseases, not only in myeloid but also in lymphoid malignancies. We detected RUNX1 mutations in 13/71 (18.3%) patients with T-ALL and thereby provided novel insights into a better molecular understanding of underlying disease mechanisms. The high incidence of RUNX1 mutations in early T-ALL may indicate an important role in early steps of hematopoietic development, yet testing of larger independent patient cohorts is required. Moreover, RUNX1
mutations were significantly associated with higher age and lower white blood cell count and characterized a novel so far not delineated poor prognostic risk group, i.e.
in the subtype of early T-ALL. Therefore, RUNX1 mutation screening is proposed in future clinical studies of T-ALL and may thus enable an even more individualized diagnosis and treatment strategy. 
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